OncoMed: Leerink Immuno-Oncology Roundtable Conference (OncoMed) - Oct 1, 2015 - "Tarextumab Phase 1B PINNACLE: Biomarker and Survival Analysis"; "Dose response and biomarker trends observed"; "Potentially longer survival noted in patients who received higher doses of tarextumab + platinum therapy and among Notch3 high patients"
P1 data • Oncology
|